Market Place
Sourcing Support
Arcturus Therapeutics To Attend Upcoming Investor Conferences
04 Nov 2025 //
BUSINESS WIRE
Arcturus’ Stock Halves on Cystic Fibrosis Readout
23 Oct 2025 //
FIERCE BIOTECH
Arcturus Sues AbbVie Over Drug-Delivery Trade Secrets
24 Sep 2025 //
REUTERS
Arcturus Therapeutics Q2 Financial Update and Pipeline Progress
11 Aug 2025 //
BUSINESSWIRE
Arcturus Therapeutics to Participate in Investor Conferences
23 Jul 2025 //
BUSINESSWIRE
Arcturus Therapeutics to Report Q1 Results on May 12, 2025
22 Apr 2025 //
BUSINESSWIRE
Arcturus Therapeutics to Present at Leerink`s Healthcare Conf.
05 Mar 2025 //
BUSINESSWIRE
Arcturus To Report Q4, Full-Year 2024 Results & Update On March 6
24 Feb 2025 //
BUSINESSWIRE
Arcturus to Present at Jefferies London Healthcare Conference
18 Nov 2024 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
27 Aug 2024 //
BUSINESSWIRE
Arcturus Therapeutics Announces Q2 2024 Update And Pipeline Progress
05 Aug 2024 //
BUSINESSWIRE
Arcturus To Report Q2 Results On August 5
18 Jul 2024 //
BUSINESSWIRE
Arcturus Updates OTC Deficiency And Cystic Fibrosis Programs
01 Jul 2024 //
BUSINESSWIRE
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
20 Jun 2024 //
BUSINESSWIRE
Arcturus Shows New CF Clinical Data At ECFC 2024
07 Jun 2024 //
BUSINESSWIRE
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
28 May 2024 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
15 May 2024 //
BUSINESSWIRE
Arcturus Therapeutics: Q1 2024 Financial Update, Pipeline Progress
08 May 2024 //
BUSINESSWIRE
Arcturus To Report Q1 2024 Results, Corporate Update on May 8
25 Apr 2024 //
BUSINESSWIRE
Arcturus Announces Fourth Quarter and Fiscal Year 2023 Financial Progress
07 Mar 2024 //
BUSINESSWIRE
Arcturus to Present at the Barclays 26th Annual Global Healthcare Conference
26 Feb 2024 //
BUSINESSWIRE
Arcturus to Report Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
BUSINESSWIRE
Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib
04 Dec 2023 //
BUSINESSWIRE
Arcturus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Dec 2023 //
BUSINESSWIRE
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
14 Nov 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Report Third Quarter Financial Results
25 Oct 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
23 Oct 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor Conferences
17 Aug 2023 //
BUSINESSWIRE
Arcturus Announces Second Quarter 2023 Financial Update and Pipeline Progress
07 Aug 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results
24 Jul 2023 //
BUSINESSWIRE
Arcturus Therapeutics Announces 1Q 2023 Financial Update and Pipeline Progress
09 May 2023 //
BUSINESSWIRE
Arcturus Announces Fourth Quarter 2022 Financial Update
28 Mar 2023 //
BUSINESSWIRE
Arcturus to Report Fourth Quarter and Full Year 2022 Financial Results
07 Mar 2023 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor Conferences
06 Feb 2023 //
BUSINESSWIRE
Arcturus to Present at the 41st Annual J.P. Morgan Healthcare Conference
19 Dec 2022 //
BUSINESSWIRE
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
13 Dec 2022 //
BUSINESSWIRE
CSL Announces Closing of Collaboration and Licensing Agreement with Arcturus
12 Dec 2022 //
PRNEWSWIRE
Arcturus Therapeutics Announces 3Q 2022 Financial Update and Pipeline Progress
09 Nov 2022 //
BUSINESSWIRE
Arcturus to Present at the Following Investor Conferences in November
07 Nov 2022 //
BUSINESSWIRE
CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine Deal
03 Nov 2022 //
BIOSPACE
CSL Enters Licensing Agreement with Arcturus for Next Generation mRNA Vaccine
01 Nov 2022 //
PRNEWSWIRE
Arcturus Announces Collaboration with CSL to Develop and Commercialize
01 Nov 2022 //
BUSINESSWIRE
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results
26 Oct 2022 //
PRESS RELEASE
Arcturus Therapeutics to Attend the Following Investor Conferences
01 Sep 2022 //
BUSINESSWIRE
Arcturus Reports Durability Data Against Omicron Variants
18 Aug 2022 //
BUSINESSWIRE
Arcturus to Report 2nd Quarter Financial Results and Provide Corporate Update
01 Aug 2022 //
BUSINESSWIRE
Arcturus Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 Jun 2022 //
BUSINESSWIRE
Arcturus Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 May 2022 //
BUSINESSWIRE
Arcturus Therapeutics Announces First Quarter 2022 Financial Update
09 May 2022 //
BUSINESSWIRE
Arcturus Reports Strong 3 Month Durability Results from ARCT-154 Booster Trial
05 May 2022 //
BUSINESSWIRE
Arcturus to Report Q1 2022 Financial Results and Provide Corporate Update
27 Apr 2022 //
BUSINESSWIRE
Arcturus` Trial for Covid-19 Vaccine Candidate Meets Primary Endpoint
21 Apr 2022 //
MARKETWATCH
Arcturus’s latecomer Covid vaccine elicits little interest
20 Apr 2022 //
EVALUATE
Arcturus Tx to Participate in Cantor Fitzgerald Virtual ROD Summit
25 Mar 2022 //
BUSINESSWIRE
Arcturus Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Mar 2022 //
BUSINESSWIRE
Arcturus Tx to Participate in the Barclays Global Healthcare Conference
14 Mar 2022 //
BUSINESSWIRE
Arcturus Tx Announces Q4 and Full Year 2021 Financial Update
28 Feb 2022 //
BUSINESSWIRE
Arcturus Tx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Feb 2022 //
BUSINESSWIRE
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Conference
08 Feb 2022 //
BUSINESSWIRE
